Liver International最新文献

{"title":"Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010–2021)","authors":"Zobair M. Younossi,&nbsp;James M. Paik,&nbsp;Yusuf Yilmaz,&nbsp;Mustafa Kanat,&nbsp;Mohamed El-Kassas,&nbsp;Said A. Al-Busafi,&nbsp;Khalid M. Al-Naamani,&nbsp;Abdel-Naser Elzouki,&nbsp;Khalid Alswat,&nbsp;Ahmed Cordie,&nbsp;Ashraf Omar Abdelaziz Osman,&nbsp;Nabil Debzi,&nbsp;Jawad Khamis,&nbsp;Mohamad Hassanein,&nbsp;Mohamed Abu-Farha,&nbsp;Fahd Al-Mulla,&nbsp;Faisal Aba-Alkhail,&nbsp;Linda Henry,&nbsp;Shira Zelber-Sagi,&nbsp;Asrar Alaklabi,&nbsp;Saleh AlQahtani","doi":"10.1111/liv.70342","DOIUrl":"https://doi.org/10.1111/liv.70342","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression. Regression modelling determined MASLD cirrhosis prevalence (compensated [CC]/decompensated cirrhosis [DCC]). Prevalence and mortality estimates were age-standardised (children and adults).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MENA region's population: progressively aged, increased (518–623 million), and experienced prevalence increases in adult diabetes (7.4%–12.1%), obesity (25.4%–31.3%) and MASLD (26.3% [117.97 million] to 27.7% [164.31 million]; APC = 0.47%; 95% CI, 0.35–0.59); steeper increase in adults ≥ 20 years (37.1%–41.0%; APC = 0.90%; 0.79–1.01). MASLD cirrhosis (0.22% [1.13 million] to 0.28% [1.73 million]; APC = 2.18%; 2.05–2.31), CC (0.20%–0.25%; APC = 2.24%) and DCC (0.020%–0.025%; APC = 2.23%) increased. Algeria, Iraq, Morocco and Turkey had the highest increases (APCs &gt; 2.8% for both CC and DCC). MASH cirrhosis mortality (APC = 0.60%), and DALYs (APC = 0.47%) increased. MASH liver cancer prevalence (APC = 2.90%), incidence (APC = 2.90%), mortality (0.50–0.69 per 100 000; APC = 2.87%) and DALYs (APC = 2.51%) increased. Iran had the most rapid increases (APC &gt; 6%) for all liver cancer outcomes; Egypt accounted for ≥ 50% liver cancer DALYs in 2021. Kuwait, West-Bank/Gaza and United Arab Emirates showed stable/declining trends.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The prevalence of MASLD and associated complications (cirrhosis and liver cancer) increased substantially across the MENA region from 2010 to 2021, with variation across countries.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma","authors":"Xiyan Xiang,&nbsp;Kirti Shetty,&nbsp;Herbert Yu,&nbsp;Bibhuti Mishra,&nbsp;Linda L. Wong,&nbsp;Xianghong Jasmine Zhou,&nbsp;Sanjaya K. Satapathy,&nbsp;James M. Crawford,&nbsp;Patricia S. Latham,&nbsp;Steven-Huy Han,&nbsp;Brandon Mathew,&nbsp;Nabil N. Dagher,&nbsp;Lawrence Lau,&nbsp;Fellanza Cacaj,&nbsp;Anil K. Vegesna,&nbsp;Srinivasan Dasarathy,&nbsp;Aiwu R. He,&nbsp;Hai Huang,&nbsp;Richard L. Amdur,&nbsp;Lopa Mishra","doi":"10.1111/liv.70325","DOIUrl":"https://doi.org/10.1111/liv.70325","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths, primarily due to late-stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Five thousand and eight serum proteins (Somascan) were analysed in Cohort A (477 CP, including 125 HCC). Clustering analysis of the TGF-β pathway-associated protein signature was performed in a longitudinal, prospective Cohort B (312 CP, in which 18 cases developed HCC over a 5-year follow-up period). Next, a multivariable prediction model was built using logistic regression analysis of cross-sectional data from a matched subgroup (<i>n</i> = 328, Cohort C). Model performance was 10-fold cross-validated across the entire Cohort A (<i>n</i> = 477).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Longitudinal follow-up analysis revealed that patients with elevated TGF-β-related protein signature displayed a five-fold increased risk of developing HCC (9.68% vs. 1.91%). Compared to cirrhosis, serum MSTN, TGFBR2, and AFP levels raised in HCC were validated by ELISA (<i>n</i> = 200, odds ratio = 1.4–2.9, <i>p</i> &lt; 0.05). In Cohort C, 88 proteins were significantly altered in HCC compared to cirrhosis (<i>p</i> &lt; 0.05). The six-protein panel (TGFBR2, MSTN, AFP, COL18A1, GLUL, TP63) displayed a strong performance in the matched cohort C (AUC 0.87, sensitivity 0.88, specificity 0.72), alongside four clinical factors (Age, Sex, BMI, Bilirubin). A 10-fold cross-validation demonstrated a mean AUC of 0.86 in cohort A, with strong predictive power in obese/MASLD/ALD-related patients (AUCs: 0.862–0.921).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The mechanism-based panel effectively stratifies HCC risk in cirrhotic patients, underscoring the need for Phase II/III validation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-Reply to Letter From Xie and Chen","authors":"Nishi H. Patel,&nbsp;Annie Y. Chen,&nbsp;Carla Osiowy,&nbsp;Valerie Durkalski Mauldin,&nbsp;William M. Lee,&nbsp;Carla S. Coffin,&nbsp;Constantine J. Karvellas,&nbsp;the US Acute Liver Failure Study Group","doi":"10.1111/liv.70345","DOIUrl":"https://doi.org/10.1111/liv.70345","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer","authors":"Mara Persano,&nbsp;Margherita Rimini,&nbsp;Lorenzo Fornaro,&nbsp;Lorenza Rimassa,&nbsp;Andrea Casadei-Gardini","doi":"10.1111/liv.70343","DOIUrl":"https://doi.org/10.1111/liv.70343","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection","authors":"Ahmed N. Farrag,&nbsp;Maggie M. Abbassi,&nbsp;Nirmeen A. Sabry,&nbsp;Tim R. Cressey,&nbsp;Philipa Easterbrook,&nbsp;Fatma S. Ebeid,&nbsp;Manal H. El-Sayed","doi":"10.1111/liv.70329","DOIUrl":"https://doi.org/10.1111/liv.70329","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14–25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to &lt; 17 kg and 17–35 kg.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Children (3–13 years; 14–35 kg) with chronic HCV received a daily paediatric formulation of DCV 30 mg and SOF 200 mg for 12 weeks. Intensive steady-state PK sampling was performed. Efficacy was assessed by sustained virologic response at 12 weeks post-treatment (SVR12), and adverse events were monitored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-three patients were enrolled in two groups: 14 to &lt; 17 kg (<i>n</i> = 11; median age 5 [3–8] years) and 17–35 kg (<i>n</i> = 12; median age 7 [5–13] years). For children 14 to &lt; 17 kg, mean (CV%) AUC24 (ng·h/mL) and <i>C</i>_maxss (ng/mL) were 14 875 (55) and 1604 (48) for DCV; 2683 (65) and 1562 (69) for SOF; and 10 456 (77) and 1420 (84) for GS-331007. For children 17–35 kg, values were 11 082 (47) and 1062 (32) for DCV; 2125 (88) and 952 (61) for SOF; and 15 256 (27) and 1606 (46) for GS-331007. All patients achieved SVR12, with good acceptability and no serious adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>For children 14–35 kg with chronic HCV, half the adult dose of DCV (30 mg) and SOF (200 mg) offered comparable exposure, safety, efficacy and acceptability to the adult regimen.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT0585451</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Translational Scope of AI-Based Fibrosis Detection in MASH","authors":"Yena Yu,&nbsp;Qingyu Chen","doi":"10.1111/liv.70339","DOIUrl":"https://doi.org/10.1111/liv.70339","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database","authors":"Alessandro Loglio,&nbsp;Ivan Gardini,&nbsp;Massimiliano Conforti,&nbsp;Marco Bartoli,&nbsp;Francesco Silvia,&nbsp;Carmine Coppola,&nbsp;Luchino Chessa,&nbsp;Gianluca Svegliati-Baroni,&nbsp;Laura Schiadà,&nbsp;Ivan Gentile,&nbsp;Biagio Pinchera,&nbsp;Maurizia Rossana Brunetto,&nbsp;Piero Colombatto,&nbsp;Alessio Aghemo,&nbsp;Stella De Nicola,&nbsp;Pierluigi Toniutto,&nbsp;Edoardo Giovanni Giannini,&nbsp;Antonio Colecchia,&nbsp;Dante Romagnoli,&nbsp;Loredana Sarmati,&nbsp;Francesca Romana Ponziani,&nbsp;Filomena Morisco,&nbsp;Calogero Cammà,&nbsp;Giuseppe Cabibbo,&nbsp;Pietro Lampertico,&nbsp;Elisabetta Degasperi,&nbsp;Pietro Invernizzi,&nbsp;Antonio Ciaccio,&nbsp;Francesco Paolo Russo,&nbsp;Antonio Massimo Ippolito,&nbsp;Grazia Anna Niro,&nbsp;Natalia Terreni,&nbsp;Gerardo Nardone,&nbsp;Alba Rocco,&nbsp;Maria D'Antò,&nbsp;David Sacerdoti,&nbsp;Donatella Ieluzzi,&nbsp;Alessia Ciancio,&nbsp;Adriano Pellicelli,&nbsp;Alessandro Federico,&nbsp;Loredana Simone,&nbsp;Vincenzo Messina,&nbsp;Ernesto Claar,&nbsp;Valerio Rosato,&nbsp;Gianpiero D'Offizi,&nbsp;Paolo Caraceni,&nbsp;Paolo Muratori,&nbsp;Cinzia Giaccherini,&nbsp;Stefano Fagiuoli,&nbsp;Mauro Viganò","doi":"10.1111/liv.70336","DOIUrl":"https://doi.org/10.1111/liv.70336","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The number of patients with a healthcare expenditure exemption for CHB (016.070.32) and CHD (016.070.33) was obtained from 21 Regional Health Authorities. To understand how many CHB or CHD patients did not have these specific exemptions, a survey was conducted in 30 Gastroenterology, Hepatology and Infectious Diseases Units across the country.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Health Authorities data reported 67 514 and 5216 subjects with an exemption for CHB and for CHD, respectively. However, among 6775 CHB and 504 CHD patients, only 60.3% and 55.7% of them had the specific exemption, respectively. Based on these results, we estimated 111 960 (95% CI: 109 780–114 240) CHB and 9360 (95% CI: 8690–10 150) CHD patients, with a prevalence of 0.22% and 0.019% of the adult overall population. Moreover, anti-HDV prevalence was 7.7% from this cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study provides a plausible estimate of the current number of adult patients diagnosed with CHB and CHD in Italy and may be considered the basis for decision-making health policies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70336","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DILI Is an Important Cause of Hepatocellular and Mixed Liver Injury—A Nationwide Prospective Study on Elevated Liver Enzymes","authors":"S. S. Sigurdarson,&nbsp;H. K. Bjornsson,&nbsp;B. L. Snorrason,&nbsp;E. S. Bjornsson","doi":"10.1111/liv.70327","DOIUrl":"https://doi.org/10.1111/liv.70327","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Very few prospective studies have investigated the most common causes of concomitant elevation of ALT and ALP. We aimed to investigate the most common aetiologies of hepatocellular or cholestatic liver injury, and to study the proportion of patients with DILI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 2-year prospective study, in Landspitali Hospital, Iceland on patients with (A) ALT &gt; 500 and (B) ALT &gt; 250 U/L and ALP &gt; 210 U/L. Appropriate diagnostic work-up was undertaken. Causality assessment in suspected DILI was with RECAM and expert opinion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 835 patients were identified with: ALT &gt; 500 U/L (<i>n</i> = 500) or ALT &gt; 250 and ALP &gt; 210 (<i>n</i> = 318), 17 were excluded due to a lack of information or elevations of non-liver related causes. Among 818 patients: 451 females (55%), median age 58 (IQR 40–72). The most common causes were choledocholithiasis 42%, ischaemic hepatitis (IH) 17%, hepato-biliary cancer (HBC) 8.4%, DILI 8.2%, viral hepatitis 6.2%, other aetiologies 11% and unknown aetiologies in 7.8%. IH was significantly more common in Group A but HBC in Group B. DILI was similar in both groups. Amoxicillin-clavulanate, checkpoint inhibitors, herbal-dietary supplements (HDS) and paracetamol were the major causative agents in DILI patients. IH and HBC patients had the highest mortality. Two DILI patients died of liver failure and one patient needed emergency liver transplantation associated with HDS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The most common cause in both groups was choledocholithiasis. IH was associated with hepatocellular injury whereas HBC was associated with cholestatic injury. DILI was an important aetiology with 8% prevalence in the cohort and was similar in the two groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort","authors":"Manon Allaire,&nbsp;Elhadji Malick Thiam,&nbsp;Guiliana Amaddeo,&nbsp;Mohamed Bouattour,&nbsp;Julien Edeline,&nbsp;Bleuenn Brusset,&nbsp;Marianne Ziol,&nbsp;Philippe Merle,&nbsp;Jean Frédéric Blanc,&nbsp;Thomas Uguen,&nbsp;Nathalie Ganne,&nbsp;Stéphane Cattan,&nbsp;Ghassan Riachi,&nbsp;Véronique Loustaud-Ratti,&nbsp;Thomas Decaens,&nbsp;Christine Silvain,&nbsp;Jean Marie Peron,&nbsp;Aurore Baron,&nbsp;Georges Philippe Pageaux,&nbsp;Frédéric Oberti,&nbsp;Rodolphe Anty,&nbsp;Alina Pascale,&nbsp;Sylvain Manfredi,&nbsp;Marc Bourliere,&nbsp;Jean Baptiste Nousbaum,&nbsp;Alexandra Heurgue,&nbsp;Isabelle Ollivier-Hourmand,&nbsp;Marie Lequoy,&nbsp;Jean Pierre Bronowicki,&nbsp;Anne Laure Villing,&nbsp;Gerard Ducournau,&nbsp;Olivier Ganry,&nbsp;Charlotte Costentin,&nbsp;Eric Nguyen-Khac","doi":"10.1111/liv.70337","DOIUrl":"https://doi.org/10.1111/liv.70337","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Atezolizumab–Bevacizumab (AtezoBev) was the first immunotherapy approved for hepatocellular carcinoma (HCC) in France, with initial trials primarily involving patients with viral-related liver disease. This prospective study aimed to evaluate the efficacy of AtezoBev in a French HCC population predominantly affected by non-viral liver disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 545 HCC patients treated with AtezoBev as first-line systemic therapy were collected from 32 French centres in the CHIEF cohort between July 2020 and January 2023. Kaplan–Meier analysis evaluated overall survival (OS) and progression-free survival (PFS), while log-rank tests assessed the impact of baseline characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median age was 69, with 81% Child-Pugh A and 19% Child-Pugh B. Liver disease was primarily alcohol-related (30%) or viral (16%), with mixed aetiology with at least alcohol consumption in 58%. At AtezoBev initiation, 72% of cases were treatment-naive, 31% were BCLC-B and 64% were BCLC-C. Median OS was 23.1 months, with a 12-month survival rate of 66%. OS was higher in BCLC-B patients (27.8 months) compared to BCLC-C (17.2 months, <i>p</i> = 0.0043) and in Child-Pugh A (26.4 months) compared to Child-Pugh B (10.6 months, <i>p</i> &lt; 0.001). Median PFS was 5.2 months, with BCLC-B patients showing significantly longer PFS (6.7 months vs. 3.7 months for BCLC-C, <i>p</i> = 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Real-world data from the CHIEF cohort demonstrate AtezoBev's effectiveness in a large French HCC population, showing survival and response rates comparable to the IMbrave150 study. These findings validate AtezoBev as effective in routine practice across diverse clinical profiles.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.70337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to ‘Socioeconomic and Geographic Factors in Liver Disease Progression Among Individuals With HIV–HBV Coinfection’","authors":"Clémence Ramier,&nbsp;Anders Boyd,&nbsp;Colette Smit,&nbsp;Patrizia Carrieri,&nbsp;Marc Van der Valk","doi":"10.1111/liv.70316","DOIUrl":"https://doi.org/10.1111/liv.70316","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}